Literature DB >> 8837710

Dopamine transporter gene polymorphism and psychiatric symptoms seen in schizophrenic patients at their first episode.

T Inada1, T Sugita, I Dobashi, A Inagaki, Y Kitao, G Matsuda, S Kato, T Takano, G Yagi, M Asai.   

Abstract

To investigate the possible role of the dopamine transporter (DAT) gene in determining the phenotype in human subjects, allele frequencies for the 40-bp variable number of tandem repeats (VNTR) polymorphism at this site were compared between 117 Japanese normal controls and 118 schizophrenic patients, including six subgroups: early-onset, those with a family history, and those suffering from one of the following psychiatric symptoms at their first episode: delusion and hallucination; disorganization; bizarre behavior; and negative symptoms. No significant differences were observed between the group as a whole or any subgroup of schizophrenic patients and controls. The results indicate that VNTR polymorphism in the DAT gene is unlikely to be a major contributor to any of the psychiatric parameters examined in the present population of schizophrenic subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837710     DOI: 10.1002/(SICI)1096-8628(19960726)67:4<406::AID-AJMG15>3.0.CO;2-N

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

1.  A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.

Authors:  Feng-Ling Xu; Mei Ding; Xue Wu; Yong-Ping Liu; Xi Xia; Jun Yao; Bao-Jie Wang
Journal:  J Mol Neurosci       Date:  2019-08-22       Impact factor: 3.444

Review 2.  Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.

Authors:  Michelle A Patriquin; Isabelle E Bauer; Jair C Soares; David P Graham; David A Nielsen
Journal:  Psychiatr Genet       Date:  2015-10       Impact factor: 2.458

3.  Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice.

Authors:  Susan B Powell; Jared W Young; Jacob C Ong; Marc G Caron; Mark A Geyer
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

4.  Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Authors:  James L Kennedy; Nian Xiong; Jinlong Yu; Clement C Zai; Jennie G Pouget; Jie Li; Kefu Liu; Hong Qing; Tao Wang; Eden Martin; Deborah L Levy; Zhicheng Lin
Journal:  Schizophr Bull       Date:  2015-12-26       Impact factor: 9.306

5.  A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men.

Authors:  William Perry; Arpi Minassian; Martin P Paulus; Jared W Young; Meegin J Kincaid; Eliza J Ferguson; Brook L Henry; Xiaoxi Zhuang; Virginia L Masten; Richard F Sharp; Mark A Geyer
Journal:  Arch Gen Psychiatry       Date:  2009-10

Review 6.  Pharmacogenomic strategy for individualizing antidepressant therapy.

Authors:  Keh-Ming Lin; Roy H Perlis; Yu-Jui Yvonne Wan
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.